Ipsen sells the North American development and marketing rights for Apokyn® to Britannia Pharmaceuticals, achieving a key milestone in the execution of its new North American strategy

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019